← Back to Analyst Consensus 
ZBIO Buy
Zenas BioPharma, Inc.
Current Price —
Implied Upside —
Analysts 14
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 4 reiterations from 3 firms
Next Earnings
Nov 18, 2026 (23 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 13, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Sep 30, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Sep 30, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Sep 30, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 14, 2026 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | — | 54% |
| Aug 14, 2026 | Guggenheim | reiterate | Buy → Buy | — | 52% |
| Aug 14, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| May 15, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| May 14, 2026 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | — | 54% |
| Mar 17, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Mar 17, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Mar 17, 2026 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | — | 54% |
| Mar 17, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Feb 10, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $44 | 44% |
| Jan 6, 2026 | Morgan Stanley | downgrade | Overweight → Equal-Weight | $19 | 54% |
| Dec 22, 2025 | Wedbush | reiterate | Outperform → Outperform | $45 | 58% |
| Nov 26, 2025 | Evercore ISI Group | initiate | — → Outperform | $55 | 58% |
| Nov 13, 2025 | Morgan Stanley | maintain | Overweight → Overweight | $37 | 54% |
| Oct 28, 2025 | Citigroup | maintain | Buy → Buy | $46 | 54% |
| Oct 28, 2025 | Morgan Stanley | maintain | Overweight → Overweight | $34 | 54% |
| Oct 28, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $44 | 44% |
| Oct 9, 2025 | Wedbush | maintain | Outperform → Outperform | $40 | 58% |
| Oct 9, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| May 16, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| Mar 20, 2025 | Wedbush | initiate | — → Outperform | $35 | 58% |
| Mar 12, 2025 | Guggenheim | reiterate | Buy → Buy | $45 | 52% |
| Mar 12, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| Feb 4, 2025 | Wolfe Research | initiate | — → Outperform | $19 | 54% |
| Dec 16, 2024 | HC Wainwright & Co. | initiate | — → Buy | $30 | 44% |
| Dec 11, 2024 | Morgan Stanley | maintain | Overweight → Overweight | $35 | 54% |
| Dec 3, 2024 | Guggenheim | reiterate | — → Buy | $0 | 52% |
Price Target Trend
Jul 24, 2026 Oct 26, 2026
EPS Estimates
0q —
+1q —
0y —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days